Revvity (Revvity) Days Sales Outstanding

: 83.75 (As of Dec. 2023)

View and export this data going back to 1983. Start your Free Trial

Revvity's average Accounts Receivable for the three months ended in Dec. 2023 was $639 Mil. Revvity's Revenue for the three months ended in Dec. 2023 was $696 Mil. Hence, Revvity's Days Sales Outstanding for the three months ended in Dec. 2023 was 83.75.

The historical rank and industry rank for Revvity's Days Sales Outstanding or its related term are showing as below:

RVTY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 72.52 Med: 80.86 Max: 128.85
Current: 82.38

During the past 13 years, Revvity's highest Days Sales Outstanding was 128.85. The lowest was 72.52. And the median was 80.86.

RVTY's Days Sales Outstanding is ranked worse than
62.67% of 225 companies
in the Medical Diagnostics & Research industry
Industry Median: 69.24 vs RVTY: 82.38

Revvity's Days Sales Outstanding increased from Dec. 2022 (71.01) to Dec. 2023 (83.75).

Revvity Days Sales Outstanding Historical Data

The historical data trend for Revvity's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

85.93

128.85

88.83

72.78

82.64

Revvity Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding																71.01	81.11	78.11	86.49	83.75

Competitive Comparison

For the Diagnostics & Research subindustry, Revvity's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revvity Days Sales Outstanding Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Revvity's Days Sales Outstanding falls into.

Revvity Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Revvity's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (612.78	+	632.811)	/	2 )	/	2750.571	*	365
=	622.7955					/	2750.571	*	365
=	82.64

Revvity's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (644.574	+	632.811)	/	2 )	/	695.901	*	365 / 4
=	638.6925					/	695.901	*	365 / 4
=	83.75

Revvity (NYSE:RVTY) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Revvity Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Revvity's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Revvity (Revvity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

PKN:Germany PKN:Germany

Address

940 Winter Street, Waltham, MA, USA, 02451

Website

https://www.revvity.com

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Executives

Anita Gonzales	officer: Please See Remarks	940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Tajinder Vohra	officer: Please See Remarks	940 WINTER STREET, WALTHAM MA 02451-1457
Prahlad R. Singh	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Joel S Goldberg	officer: See Remarks	940 WINTER STREET, WALTHAM MA 02451
Michelle Mcmurry-heath	director	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett	director	C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alexis P Michas	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Pascale Witz	director	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121